What does the future hold for the patient with peripheral arterial disease?

European Heart Journal, Supplement

Volumn 6, Issue 3, 2004, Pages

  Sillesen, H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular risk factor management; Intermittent claudication; Interventional therapy; Lipid lowering therapy; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PHOSPHODIESTERASE INHIBITOR; RAMIPRIL; SIMVASTATIN;

ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TECHNIQUE; ULTRASOUND; VASCULARIZATION; X RAY;

EID: 3042588118     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.04.008     Document Type: Article

References (24)

1. Criqui M.H., Fronek A., Barrett-Connor E., et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 71:1985;510-515
2. Vogt M.T., Wolfson S.K., Kuller L.H. Lower extremity arterial disease and the aging process: a review. J. Clin. Epidemiol. 45:1992;529-542
3. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326:1992;381-386
4. Hertzer N.R., Beven E.G., Young J.R., et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann. Surg. 199:1984;223-223
5. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler. Thromb. Vasc. Biol. 19:1999;538-545
6. Perkins J.M., Collin J., Creasy T.S., et al. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur. J. Vasc. Endovasc. Surg. 11:1996;409-413
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
8. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
9. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:2000;145-153
10. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
14. Blankenhorn D.H., Azen S.P., Crawford D.W., et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 83:1991;438-447
15. The lipid research clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64
16. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. 323:1990;946-955
17. Pedersen T.R., Kjekshus J., Pyorala K., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am. J. Cardiol. 81:1998;333-335
18. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
19. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344:2001;1608-1621
20. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9
21. Bismuth J., Klitfod L., Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur. J. Vasc. Endovasc. Surg. 21:2001;143-146
22. Nass C.M., Allen J.K., Jermyn R.M., et al. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vasc. Med. 6:2001;35-41
23. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 286:2001;1317-1324
24. Mohler E.R. 3rd, Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 108(12):2003;1481-1486